Federal Court Allows Shareholder Lawsuit Against Medtronic Alleging Fraud Regarding Infuse Product to Go Forward
In the final days of 2016, a federal appellate court revived a lawsuit brought by a group of shareholders accusing Medtronic, a major medical device and technology company, of concealing information about the negative impacts of its bone growth protein product, Infuse, for over 10 years.
According to the United States Court of Appeals for the Eighth Circuit, a lower court judge incorrectly concluded that the plaintiffs filed their action outside the statute of limitations. According to the lower court record, the plaintiffs did not file their complaint until two years after they learned about Medtronic’s alleged fraudulent activity. The lawsuit also states that executives at the company were not truthful with investors regarding the commercial viability and safety aspects of the Infuse bone growth protein. They also allege that company analysts were not truthful about the prospects of a possible follow-on product, Amplify.
The complaint states that the shareholders purchased shares of Medtronic stock in reliance on these misrepresentations and suffered serious financial harm when the stock price crashed after numerous reports questioning the safety of Medtronic’s Infuse product surfaced. These reports and numerous lawsuits filed against Medtronic allege that the Infuse bone growth paste was used in countless off-label procedures.